[📢 BRENUS Pharma unveils groundbreaking preclinical results for STC-10101 , a promising new drug candidate targeting Colorectal Cancer & Solid Tumors. #AACR23]
DOWNLOAD PRÂ
AACR Annual meeting 2023
Inovative in vivo (in ovo) CAM model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on human colorectal adenocarcinoma F. Ghiringhelliet al, Cancer Res 2023; 6791. https://doi.org/10.1158/1538-7445.AM2023-6791 Link to poster STC-1010 a new therapeutic vaccine promotes tumor cell death A. Italiano et al, Cancer Res 2023; LB224.https://doi.org/10.1158/1538-7445.AM2023-LB224 Link to Poster
[📢 French Blood Establishment (EFS) & Brenus Pharma partner for the GMP production of STC-1010, an innovative therapy against colorectal cancer]
French Blood Establishment (EFS) & Brenus Pharma partner for the GMP production of STC-1010, an innovative therapy against colorectal cancer – DOWNLOAD PR
[📢Pharma announces its Strategic Committee supporting & ensuring its value-creating strategic plan]
DOWNLOAD PRESS RELEASEÂ
[📢Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010]
DOWNLOAD PR Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010.
[📢Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010]
Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010 DOWNLOAD PRÂ
SITC annual meeting 2022
Efficacy study of STC-1010 antitumor vaccine associated with standard chemotherapies on MC 38 syngeneic colon cancer tumor model F. Ghiringhelli et al, Journal for ImmunoTherapy of Cancer 2022; 1179Â doi: 10.1136/jitc-2022-SITC2022.1179 Link to poster Inovative in vivo (in ovo) cam model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on human colorectal adenocarcinoma F. Ghiringhelli et al, Journal for ImmunoTherapy of Cancer 2022; 949 http://dx.doi.org/10.1136/jitc-2022-SITC2022.0949 Link to Poster
AACR annual meeting 2022
Sensitizing potential of a novel stimulated and haptenized vaccine in immunotherapy resistant metastatic colorectal cancer R. Boidot et al, Cancer Res 2022; 3566. https://doi.org/10.1158/1538-7445.AM2022-3566 Link to Poster Antitumor activity of a novel allogeneic colorectal cancer vaccine in C57BL/6 mice bearing MC38 anti-PD1 resistant colon carcinoma syngeneic model with TME A. Italiano et al, Cancer Res 2022; 2051. https://doi.org/10.1158/1538-7445.AM2022-2051 Link to Poster
AACR 2021 Annual Conference
Efficacy results of a novel vaccine composed of stimulated and haptenized tumors cells in Balbc mice grafted with murine colon adenocarcinoma CT26 cells C. Gongora et al, Cancer Immunol Res 2022; P003. https://doi.org/10.1158/2326-6074.TUMIMM21-P003 Link to PDF presentation